Cue Biopharma (NASDAQ:CUE) Shares Up 34.8% – What’s Next?

Cue Biopharma, Inc. (NASDAQ:CUE)’s stock price shot up 34.8% during mid-day trading on Friday . The company traded as high as $0.3324 and last traded at $0.3248. 7,086,842 shares changed hands during trading, an increase of 888% from the average session volume of 716,938 shares. The stock had previously closed at $0.2410.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Cue Biopharma Stock Up 34.8%

The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.57 million, a price-to-earnings ratio of -0.71 and a beta of 1.39. The business’s fifty day moving average is $0.58 and its two-hundred day moving average is $0.70.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. Cue Biopharma had a negative net margin of 530.75% and a negative return on equity of 271.67%. The business had revenue of $2.15 million during the quarter, compared to the consensus estimate of $2.29 million. Equities analysts forecast that Cue Biopharma, Inc. will post -0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cue Biopharma

Several institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma in the 3rd quarter valued at $62,000. Angeles Wealth Management LLC purchased a new stake in Cue Biopharma in the second quarter valued at $82,000. Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma during the third quarter worth about $439,000. Finally, GC Wealth Management RIA LLC purchased a new stake in shares of Cue Biopharma in the 2nd quarter valued at about $2,273,000. 35.04% of the stock is owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.